Tags : Intraocular Inflammation

Novartis’ Beovu (brolucizumab) Receives EMA’s Approval for its Safety Label

Shots: The EU label update includes additional categorization of retinal vasculitis and/or retinal vascular occlusion, usually in the intraocular inflammation. The approval follows Novartis completion of safety review and initiation of update to the Beovu prescribing information globally The label update is applicable to all 27 EU member states as well as UK, Iceland, Norway, […]Read More